NanoSyrinx develops a novel 'nanosyringe' platform designed to deliver complex biologic payloads selectively.

NanoSyrinx

Kebotix provides R&D solutions through enterprise AI customized for materials discovery, leveraging cloud technologies, machine learning, and automation.

Kebotix

NanoSyrinx develops a novel nanosyringe platform to deliver complex biologic payloads selectively. This information is self-described.

NanoSyrinx | 1,743 followers on LinkedIn. NanoSyrinx is developing a novel Biologics drug delivery system for the biopharmaceutical sector. | NanoSyrinx is a cutting-edge synthetic biology company creating the next generation of targeted drug delivery systems to address challenges in the biologic delivery sector.

Jane Dancer

Board Chair, Outrun Therapeutics and Board Member, NanoSyrinx

Anthony G Johnson

Chief Business Officer at NanoSyrinx

James Lapworth

Associate Principal Scientist at Nanosyrinx

Kiran Chintakayala

Kicking off day 3 of #ENASymp24 ! On top of a series of great talks today, we will also be sharing the exciting results from one of our internal projects at poster board #355! If you're sticking around and you're interested in targeted intracellular protein delivery and what we do at NanoSyrinx, come along for a chat with me and Marie McAvoy . EORTC - European Organisation for Research and Treatment of Cancer National Cancer Institute (NCI) American Association for Cancer Research #biotech #drugdelivery #proteindelivery #synbio #intracellulardelivery

Alex Titimeaua

Meet my NanoSyrinx colleagues Alex Titimeaua and Marie McAvoy at #ENASymp24 presenting a poster on payload delivery in Barcelona this week.

Sabine Bowman-Grahl

Hello LinkedIn! Hot on the heels of our recent £10M financing, NanoSyrinx is #hiring . Know anyone who might be interested? For these roles we are looking for experienced scientists with fantastic depth of knowledge who are keen to contribute to an exciting biotech journey! We have 2 live roles currently: 🧬 Preclinical R&D lead for Translational Biology https://lnkd.in/g96FejCJ 🧪 Upstream Bioprocess Lead https://lnkd.in/ggM2ASzH We will have some additional roles coming out in the next few days so please check www.nanosyrinx.com/careers or NanoSyrinx for more details. Any shares/recommendations etc much appreciated. #biotech #syntheticbiology #drugdiscovery #drugdelivery

Joe Healey

Empowering Innovation, Supporting Growth: NanoSyrinx Hits Major Milestone We’re proud to have supported the NanoSyrinx team on their journey. Their recent £10M fundraising round is the latest remarkable step in its outstanding growth. 🔬NanoSyrinx, a synthetic biology company, is developing nanosyringes—a novel platform for targeted intracellular delivery of biologic therapeutics. This technology has the potential to unlock treatments for previously ‘undruggable’ intracellular targets, driving a new wave of medical innovation. Here's how we've supported NanoSyrinx so far : 🚀 Attended our Pre-Accelerator Workshop (2019): Helping to refine their business model and strategy. 💡 Supported in multiple funding rounds (2020-2022): Helping the team to raise the capital needed to scale. 🎟️ Awarded our Golden Ticket in Partnership with AbbVie : One year of free lab space and mentorship. Now, with new funding and the appointment of Dr. Edwin Moses as Chairman, the company continues to push the boundaries of biological therapies. Explore the full story here 👇 https://lnkd.in/eQSuQiNR

Pioneer Group

With the support of Eli Lilly and other investors, NanoSyrinx aims to revolutionize drug delivery using its novel nanosyringe platform. #IntracellularDelivery #DrugDeliveryTech #BiotechFunding #NanoSyrinx #PharmaInnovation #NextGenTherapies

SynBioBeta

Congratulations to NanoSyrinx after completing a £10 million financing round!! #news

Warwick Innovation District

“While huge advances have been made in the field of biologic therapies, the delivery challenge remains a key bottleneck." NanoSyrinx , a synthetic biology company developing nanosyringes as a novel platform for targeted intracellular delivery of biologic therapeutics, has announced that it has closed a 10 million GBP financing round. The company also announced the appointment of Dr. Edwin Moses as Chairman of the Board of Directors. Read more: https://lnkd.in/eQNndesz #MedTech #Funding #NanoSyringes #MedicalDevices

Med-Tech Innovation

📣📣📣HUGE NEWS 📣📣📣 Today we are announcing that NanoSyrinx has completed a £10 million ($13 million) financing round, to accelerate the development of our unique nanosyringe platform for intracellular drug delivery. 🚀 The round was co-led by BGF , Octopus Ventures and M Ventures , with support from new corporate investor, Eli Lilly and Company , and existing investors, IQ Capital and Meltwind Advisory LLP . But there’s more… 😲 We are thrilled to announce that Edwin Moses has joined NanoSyrinx as Chairman, succeeding Stephen Taylor who has led the board since the Company’s inception. As part of the fundraise, we are also delighted to welcome Lucy Edwardes Jones (BGF) to the Board, who will serve alongside existing directors Oliver Sims (Octopus Ventures), Bauke Anninga, PhD (M Ventures), Jane Dancer (Independent) and Anthony G Johnson (Independent). 🗞️ For more details, check out our press release here: https://lnkd.in/eTx89F7C

Metric
Company Name	NanoSyrinx	Kebotix
Symbol
MSH ID	COM:NANOSYRINX	COM:KEBOTIX
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Technology
Industry	Biotechnology	Materials Science
Country	GB	US
Stage
Employee Count
Website	nanosyrinx.com	kebotix.com
LinkedIn	nanosyrinx
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

NANO

COM:NANOSYRINX

NanoSyrinx

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue